Plasma levels of TNF-alpha in sickle cell patients receiving hydroxyurea.
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D001157:Arterial Occlusive Diseases / Q000139:chemically induced; D016022:Case-Control Studies; D004341:Drug Evaluation; D005260:Female; D005319:Fetal Hemoglobin / Q000096:biosynthesis / Q000187:drug effects; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000187:drug effects*; D019010:Vascular Cell Adhesion Molecule-1
D014409:Tumor Necrosis Factor-alpha; D019010:Vascular Cell Adhesion Molecule-1; D009569:Nitric Oxide; D005319:Fetal Hemoglobin; D006918:Hydroxyurea